PTAA and B10: new approaches to amyloid detection in tissue-evaluation of amyloid detection in tissue with a conjugated polyelectrolyte and a fibril-specific antibody fragment

• Published in: Amyloid Vol. 18; no. 2; pp. 47 - 52
• Main Authors: Kieninger, Barbara, Gioeva, Zarina, Krüger, Sandra, Westermark, Gunilla T., Friedrich, Ralf P., FÄndrich, Marcus, Röcken, Christoph
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01-06-2011; Taylor & Francis
• Subjects: Acetates - chemistry; amyloid; Amyloid - analysis; Amyloidosis - diagnosis; Amyloidosis - pathology; Animals; Antibodies - chemistry; Biopsy; camelid antibody; Camelus - immunology; Congo Red - chemistry; Humans; MEDICIN; MEDICINE; Polymers - chemistry; PTAA; Registries; Staining and Labeling - methods; Thiophenes - chemistry
• ISSN: 1350-6129; 1744-2818; 1744-2818
• DOI: 10.3109/13506129.2011.560623

Aims: We analysed the suitability of two little known substances for the detection of amyloid in surgical pathology specimens, that is the conjugated polyelectrolyte polythiophene acetic acid (PTAA) and the camelid antibody domain B10.
Methods: We compared the amyloid detection of PTAA and B10 to Congo red in 106 amyloid-containing tissue biopsies of diverse anatomical and precursor origin by evaluating the accordance in four grades (grade 0: no staining, grade 1: staining of <33% of the amyloid deposits, grade 2: 33-66% and grade 3: >66%).
Results: PTAA showed grade 2-3 staining in 57 (54%) cases, while B10 presented this accordance in only 25 (24%) tissue biopsies. Grade 1 staining was found in 11 (10%) samples with PTAA and in 62 (58%) cases with B10. No staining at all (grade 0) occurred in 38 (36%) biopsies when using PTAA and in 19 (18%) cases when using B10.
Conclusion: Although conformation-sensitive detection seemed promising, PTAA and B10 stain only a fraction of the examined amyloid samples when using routine surgical pathology settings. This study emphasises the necessity of having optimised pre-analytical protocols for recovery, storage and handling of samples if these novel amyloid ligands are to be used in routine diagnosis of amyloid.